title: Prognoses of MDS subtypes RARS, RCMD and RCMD-RS are comparable but cytogenetics separates a subgroup with inferior clinical course.
abstract: In 2008, the WHO combined the former categories RCMD (refractory cytopenia with multilineage dysplasia) and RCMD-RS (ring sideroblasts ≥ 15%). We studied the clinical impact and genetic background of RARS, RCMD, and RCMD-RS in 1082 patients. Good karyotypes (IPSS) were similarly frequent in RARS, RCMD, and RCMD-RS. 2-year overall survival (OS) rates were similar in RARS, RCMD, and RCMD-RS (85.9%/89.0%/91.7%; n.s.). The 2-year OS rate was better in good than intermediate or poor karyotypes (p<0.001). These results support to combine RCMD and RCMD-RS as performed by WHO and emphasize the prognostic power of cytogenetic criteria for these MDS subtypes.
authors.affiliation: Department for Stem Cell Transplantation, University of Hamburg, Germany.
authors.forename: Ulrike
authors.initials: U
authors.lastname: Bacher
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Kern
authors.forename: Tamara
authors.initials: T
authors.lastname: Alpermann
authors.forename: Susanne
authors.initials: S
authors.lastname: Schnittger
authors.forename: Claudia
authors.initials: C
authors.lastname: Haferlach
authors.forename: Torsten
authors.initials: T
authors.lastname: Haferlach
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000753:Anemia, Refractory / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics / Q000401:mortality; D000756:Anemia, Sideroblastic / Q000175:diagnosis* / Q000453:epidemiology / Q000235:genetics / Q000401:mortality; D015331:Cohort Studies; D003582:Cytogenetics / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000145:classification* / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality; D011379:Prognosis; D016019:Survival Analysis; D055815:Young Adult